

# Pipeline

	Indication/Target	Program	Preclinical	Phase 1	Phase 2	Phase 3	Trial Name / Collaborator
Late stage	<b>NSCLC (2<sup>nd</sup>/3<sup>rd</sup> line)</b>	Plinabulin + Docetaxel					DUBLIN-3
	<b>CIN Prevention</b>	Plinabulin; Plinabulin + Pegfilgrastim					PROTECTIVE-1 & PROTECTIVE-2
Investigator Initiated Trials	<b>SCLC (2<sup>nd</sup>/3<sup>rd</sup> line)</b>	Plinabulin + PD-1 + CTLA-4					Bristol Myers Squibb™ RUTGERS
	<b>7 cancers (PD-1/PD-L1 failed)</b>	Plinabulin + PD-1/PD-L1 + Radiation					THE UNIVERSITY OF TEXAS MD Anderson Cancer Center
	<b>AHCT (hematopoietic stem cell transplantation) in Multiple myeloma</b>	Plinabulin + Pegfilgrastim					Memorial Sloan Kettering Cancer Center
Early Stage	<b>Preclinical assets</b>	BPI-002, BPI-003, BPI-004					
SEED Therapeutics	<b>KRAS and additional targets</b>	Targeted Protein Degradation (TPD) Molecule Glue Platform					SEED THERAPEUTICS
	<b>Multiple Targets</b>	TPD (Molecular Glue)					Lilly